Home Press Press Releaeses Press Releases +++ Eisbach receives IND clearance for lead candidate EIS-12656, a first-in-class allosteric inhibitor of ALC1, from the FDA ++++++ Insempra completes $20 million financing to advance the development of next-generation bio-based ingredients. ++++++ Tubulis presents novel preclinical data for its lead ADC candidates targeting solid tumors at AACR 2024 ++++++ Eisbach receives USD 4.5 million investment from Cancer Focus Fund to support Phase 1/2 trial of lead candidate EIS-12656 ++++++ Tubulis secures significant EUR 128 million Series B2 financing ++++++ Novel small molecule drugs of the future targeting the CNS ++++++ Christian Gnam succeeds Dr. Peter Zobel as new Managing Director of the Biotechnology Innovation and Start-up Center (IZB) ++++++ Thermosome advances Phase I trial with lead candidate THE001 to next dose level ++++++ MorphoSys enters into Business Combination Agreement to be Acquired by medicines company Novartis ++++++ CatalYm strengthens Board of Directors and Scientific Advisory Board with key appointments ++++++ Tubulis out-licenses IND-ready ADC for the treatment of lymphoma to Oncoteq ++++++ MorphoSys ends the year with positive phase 3 data and successful cash capital increase of approximately EUR 102.7 million ++++++ Oncology experts to support the development of Thermosome’s clinical candidate THE001 ++++++ Renowned Peutinger-Collegium visits the IZB ++++++ SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878 ++++++ GoingPublic celebrates a quarter century of biotech ++++++ 4SC’s resminostat receives Orphan Drug Designation from the European Medicines Agency ++++++ Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell ++++++ Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology ++++++ High-Profile Clinical Advisory Board for Thermosome ++++++ Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker ++++++ MorphoSys’ program tulmimetostat receives FDA Fast Track designation ++++++ adivo becomes part of the world’s leading animal health company Zoetis ++++++ The Munich Bavaria Student Union visits the IZB ++++++ Bind-X secures €10 million in financing as part of its Series B financing round ++++++ Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research ++++++ 23 students from Europe visited the IZB as part of the AMGEN Scholar Program ++++++ M1 – Munich Medical Alliance: Becoming Germany’s No. 1 medical hub ++++++ Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy ++++++ Vivoryon Therapeutics highlights progress of lead candidate varoglutamstat in Alzheimer’s disease ++++++ leon-nanodrugs welcomes Dr. Hans Frickel as new CEO ++++++ Pioneering research projects at the 8th Life Science Pitch Day at the IZB ++++++ Japanese delegation visits the IZB ++++++ Bavarian biotechnology maintains its position in the crisis and continues to grow ++++++ Biotech company Origenis welcomes Prof. Hendrik Liebers as Chairman of the Board ++++++ Official handover ceremony at the Annual Meeting of the Max Planck Society ++++++ Secarna appoints new Chief Business Officer ++++++ Bicoll showcases at BIO International Convention ++++++ Thermosome joins IMAGIO consortium to advance development of cancer therapies for soft tissue sarcoma ++++++ Breakthrough in fluorescence microscopy at the Max Planck Institute of Biochemistry ++++++ New preclinical data show long-term antitumor effects of Secarna Pharmaceuticals’ antisense oligonucleotide (ASO) therapies ++++++ Biotech report by vfa: Biopharmaceuticals successfully gain market share ++++++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa ++++++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics ++++++ Non-nutritive sweeteners may affect the human immune system ++++++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” ++++++ Invitris receives 250,000 EUR to complete spin-out from TUM ++++++ Eisbach starts phase I clinical trial with COVID-19 antiviral ++++++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park ++++++ Specific packaging of DNA affects cell division ++++++ Tubulis Enters Strategic Partnership with BMS ++++++ Insempra launches its first functional component for consumer goods ++++++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman ++++++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease ++++++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership ++++++ adivo expands into new headquarters as first clinical study begins ++++++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial ++++++ Construction of the “New Hauner” at the Grosshadern Campus has started ++++++ Insempra names new Chief Operating Officer ++++++ Training events for project managers and biological safety officers ++++++ The zebrafish brain as a map ++++++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure ++++++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris ++++++ When life begins too early ++++++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease ++++++ Expansion of the Munich “science line” has started ++++++ Enno Spillner to join Formycon as CFO +++ PDF archive 2018 11. October 2018Gilead Sciences, ChromoTek and Johnson & Johnson Innovation present at the Biotech Press Lounge 20. August 2018Pet therapeutic antibody firm adivo announces closure of seed-financing round 2. August 2018GNA Biosolutions, a Munich based Biotech Company, wins AACC’s Disruptive Technology Award in Chicago 14. June 2018Innovative start-ups present to leading life science investors at the IZB 26. May 2018New ways to invest in cancer drugs 22. March 2018Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer 15. March 2018Origenis Appoints Thomas Loeser as Chief Financial Officer 8. February 2018New Technologies from the IZB are revolutionizing medical diagnostics 2017 5. September 2017Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million 6. July 2017Start-ups profit from being in close contact with the venture capital scene 3. April 2017Europe-wide event series is very popular 12. January 2017Breakthrough technology improves genetic stem cell therapies 2016 10. November 2016Evotec and Oxford create novel partnership called “LAB282” 4. October 2016Evotec and Carrick Therapeutics build strategic alliance 29. September 2016Evotec receives further important pre-clinical milestone in endometriosis alliance with Bayer 13. September 2016LEUKOCARE grants license to US vaccine company PaxVax 9. June 2016Bicoll moves into the leading European biotech cluster 15. April 2016WuXi AppTec Acquires Crelux 2015 5. October 2015Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center 15. September 2015‘Bodyguard’ Protein Helps Protect Young RNAs 26. August 2015„Bone adhesive“ – Innovative medicine starts as BMWi-project Biopolymers shall revolutionize the treatment of bone injuries 1. July 2015Molecular diagnostics specialist GNA Biosolutions completes € 6 million (US$ 6.7m) financing round 24. June 2015CRELUX receives 800 000 euros funding within the EU HORIZON 2020 programme to identify compounds from marine sources for age-related disease therapy 2014 5. December 2014ChromoTek strengthens its position in the highly important US market 24. July 2014CRELUX and 4SC Discovery awarded research grant for new epigenetic cancer drugs 28. May 20144SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO 24. March 2014ChromoTek and NMI TT ally to start a new chapter in cellular high content analysis 2013 10. December 2013Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim 21. October 2013Evotec enters integrated alliance with AstraZeneca in kidney disease 16. October 2013Evotec to hold R&D Day 2013 10. October 2013Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways 30. September 2013Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim 10. September 2013SuppreMol appoints industry expert Michael Tansey as Chief Development Officer 8. August 2013Evotec AG reports H1 2013 results 8. August 20134SC reports second quarter 2013 financial results 1. August 20134SC to host conference call on 8 August 2013 to present half year results 2013 25. July 20134SC’s partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in non-small-cell lung cancer (NSCLC) in Japan 21. May 2013SuppreMol Raises € 9.5 million in Extended Series D Financing Round 16. May 2013Evotec and Harvard University to collaborate on development of new class of antibacterials 14. May 20134SC significantly improves operating result in first quarter of 2013 and resolves to focus its development strategy 10. May 20134SC to host conference call on 14 May 2013 to present first quarter results of 2013 30. April 2013Dana-Farber’s Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology 18. April 2013ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells 26. March 2013Forward step by step with Action Plan 2016 – Continued revenue growth – Significant pipeline progress 25. March 20134SC announces financial results for a successful year 2012 18. March 20134SC to host conference call and webcast on 25 March 2013 to present full year financial results for 2012 11. March 2013ibidi is a Top Winner in the 2012/13 German Economy Innovation Award Competition 6. March 20134SC AG: Dr Ulrich Dauer to step down as CEO and member of the Management Board on 31 March 2013; his successor will be CFO Enno Spillner 26. February 20134SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases 20. February 20134SC Discovery and BioNTech launch strategic cancer therapy research partnership 11. January 2013Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd. 9. January 2013Evotec and Yale University form Open Innovation Alliance 8. January 20134SC obtains key patent for anti-cancer compound resminostat in Europe 7. January 2013Evotec expands collaboration with MedImmune, receives milestone payment 3. January 2013Evotec acquires Cell Culture Service GmbH 2. January 2013Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy 2012 17. December 2012Evotec announces NMDA antagonist license agreement 28. November 2012Evotec enters biology collaboration with Probiodrug 23. November 2012Evotec Receives CIR (French Research Tax Credit) Accreditation 8. August 2012Evotec H1 2012: Building innovation on the back of profitable growth 28. June 20124SC to present additional safety and efficacy data for cancer drug Resminostat from its Phase II SHELTER trial in liver cancer at ESMO GI Cancer Meeting 2011 5. September 2024Record financing rounds at the Munich biotech hub 17. July 20249th Munich Life Science Pitch Day 17. July 2024Life Science Pitch Day at the IZB: Innovations meet Investors 8. March 2024Newsletter 02/24 8. March 2024Christian Gnam succeeds Dr. Peter Zobel as new Managing Director of the Biotechnology Innovation and Start-up Center (IZB) 19. February 2024A year of successes and changes at Munich’s biotech hub 14. February 2024Newsletter 01/24 30. December 2023Newsletter December 2023 12. December 2023Novogene expands its European operations with new genomics facility at the IZB in Munich, Germany 28. November 2023MoleQlar receives seed funding from Rheingau Founders and acquires Munich-based epigenetics specialist EpiQMAx 11. November 2023Newsletter November 2023 6. November 2023Presentation of IZB’s innovation powerhouse in the context of BIO-Europe 2023 6. November 2023Netzwerkveranstaltung BioEurope 2023 11. October 2023GoingPublic.de – Life Sciences 10-23 25. September 2023Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell 22. September 2023Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker 22. September 2023Wirtschaftsempfang / Economic reception 2023 1. August 2023Bind-X secures €10 million in financing as part of its Series B financing round 31. July 2023Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research 25. July 2023Viopas Venture Consulting opens office in the Innovation and Start-up Center Biotechnology (IZB) 19. July 20238th Munich Life Science Pitch Day 14. July 2023Pioneering research projects at the 8th Life Science Pitch Day at the IZB 14. July 20238th Munich Life Science Pitch Day 1. July 2023Newsletter July 2023 10. May 2023Venture Capital Magazine 05-23 1. May 2023Newsletter May 2023 27. April 2023Innovation and Start-up Center Biotechnology (IZB) welcomes LEON 20. April 2023Tubulis Enters Strategic Partnership with BMS 1. April 2023Newsletter April 2023 28. March 202316th Biotech Press Lounge 28. March 2023IZBrunch, February 2023 28. March 2023IZBrunch, November 2022 16. March 202316th Biotech PressLounge 16. March 202316th Biotech Press-Lounge at the IZB: A new “atlas for human heart cells” may lead to customized and personalized therapies in the future 10. March 2023Plattform Life Sciences 03-23 1. March 2023Newsletter March 2023 27. February 2023Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris 1. February 2023Newsletter February 2023 31. January 2023Successful year for the Munich biotech hub 11. January 2023Venture Capital Magazine 01-23 21. December 2022Innovation and Start-Up Center for Biotechnology (IZB) welcomes T-CURX GmbH 22. November 2022Atriva Therapeutics GmbH moves into the Innovation and Start-Up Center for Biotechnology (IZB) 11. November 2022Plattform Life Sciences 11-22 10. November 2022Plattform Life Sciences 11-22 9. November 2022Venture Capital Magazine 06-22 9. November 2022Venture Capital Magazine 06-22 28. October 2022Süddeutsche Zeitung 2022 20. October 2022Innovation and Start-Up Center for Biotechnology (IZB) welcomes consultancy KLIFO 17. October 2022VC investor Andera Partners opens office in the Innovation and Start-up Center Biotechnology (IZB) 12. October 20227th Munich Life Science Pitch Day 12. October 202215th Biotech Press Lounge 7. October 2022Munich Life Science Pitch Day at the IZB: Eleven teams presented to 28 life science investors with an available investment volume of more than 20 billion euros 7. October 20227th Munich Life Science Pitch Day 1. October 202215th Biotech PressLounge 1. October 202215th IZB Biotech Press Lounge: The cocktail for medical progress 10. September 2022Plattform Life Sciences 09-22 22. July 2022IZBrunch vom 21. Juli 2022 14. July 2022Cutting-edge research at Munich’s IZB attracts strong interest 5. July 2022IZBrunch June 30, 2022 22. June 2022Wirtschaftsempfang / Economic reception 2022 22. June 2022Business reception at the Biotechnology Innovation and Start-up Center (IZB) above the roofs of the campus 10. May 2022Plattform Life Sciences 05-22 3. May 2022Tubulis closes a series B financing in the amount of 60 million and moves into IZB in June 2022 14. April 2022Interview Dr. Zobel, münchenTV 31. March 202214th Biotech Press Lounge 23. March 202214th Biotech Press Lounge 23. March 202214th Biotech Press Lounge of the IZB: Medical innovations that are changing the world 10. March 2022Venture Capital Magazine 03-22 10. March 2022Plattform Life Sciences 03-22 24. February 2022Innovation and Start-Up Center for Biotechnology (IZB) welcomes new start-up Origin.Bio 31. January 2022Süddeutsche Zeitung 2022 29. January 2022Münchner Merkur 01-22 28. January 2022dpa 01-22 28. January 2022Munich’s Biotech Valley IZB is Booming 20. January 2022SCG Cell Therapy expands global R&D by opening a research innovation site at the IZB in Germany 19. January 2022PreOmics receives Euro 13.5 million from Bruker Corporation in Series B financing round 5. November 2021IZBrunch, October 21, 2021 3. November 2021Eisbach Bio receives 6.7 million Euros grant from the Bavarian Government 6. October 2021mk2 Biotechnolgies new start-up at the Innovation and Start-up Center Biotechnology (IZB) in Martinsried, near Munich, Germany 5. October 2021IZBrunch, September 23, 2021 5. October 20216th Munich Life Science Pitch Day 1. October 2021Innovative drug developers presented to over 20 investors at the Munich Start-Up Center 1. October 20216th Munich Life Science Pitch Day 8. July 2021COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant 5. July 202130.09.2021: Life Science Pitch Day in cooperation with High-Tech Gründerfonds, Bayer AG, Boehringer Ingelheim and IZB 1. July 2021Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021 12. May 2021AMSilk receives financing of 29 million euros 13. April 2021Lindis entwickelt Immuntherapie gegen Blasenkrebs 13. April 2021Lindis Biotech develops immunotherapy against bladder cancer 17. March 2021CHEManager 2021 10. March 2021Münchner Merkur 2021 1. March 2021Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins 25. February 2021ChromoTek and Absolute Antibody Collaborate on Recombinant Engineered Antibodies 11. February 2021A higher omega-3 level apparently protects from dying from COVID-19 4. February 2021World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools 3. December 2020Innovation network Proteomics4Future explores new technologies for the industrialization of MS-based proteomics 23. November 2020Proteintech uand Chromo Tek, 2020 23. November 2020Handelsblatt, 2020 23. November 2020IHK Magazine, 07-2019
